A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
← catalyst calendarNCT07023289 · readout ≤ 1,199 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
140estimated
Sites
48
Countries
Belgium, Denmark, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-02 | actual | When the study began enrolling |
| Primary completion | Nov 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colorectal Cancer
Interventions
- Drug: Telisotuzumab Adizutecan
- Drug: Standard of Care
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with disease free survival (DFS) Event
measured Up to Approximately 51 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed